Related Experiment Videos
Aminotransferase as a prognostic index in infants with liver disease
1Department of Pediatrics, Childrens Hospital of Los Angeles, CA.
Insights
The serum aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio can predict infant liver disease outcomes. An increasing AST/ALT ratio indicates a poor prognosis in infants with hepatic disease.
Area of Science:
- Pediatric Hepatology
- Biomarker Research
- Prognostic Indicators
Background:
- Chronic liver disorders in infants present diagnostic challenges.
- Early identification of prognosis is crucial for managing pediatric liver disease.
- The utility of the AST/ALT ratio in infant liver disease requires further investigation.
Purpose of the Study:
- To evaluate the prognostic value of the serum aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio in infants with chronic liver disorders.
- To determine if the AST/ALT ratio can differentiate between good and poor outcomes in this population.
- To assess the AST/ALT ratio as an early and reliable prognostic indicator.
Main Methods:
- Retrospective analysis of medical charts from 73 infants with chronic liver disorders.
- Categorization of patients into good (n=40) and poor (n=33) outcome groups based on clinical course.
- Measurement of serum AST and ALT levels at presentation and during follow-up (first 13 months).
Main Results:
- No significant difference in AST/ALT ratios between good and poor outcome groups at initial presentation (mean age 1.65 months).
- The AST/ALT ratio demonstrated a significant change over time: it increased in the poor-outcome group and decreased in the good-outcome group.
- The dynamic change in AST/ALT ratio over time proved to be a key differentiator.
Conclusions:
- The serum AST/ALT ratio is a valuable, easy-to-use, and early prognostic indicator for infants with hepatic disease.
- Monitoring the AST/ALT ratio over time can aid in evaluating disease progression and patient outcomes.
- This biomarker may assist clinicians in managing infants with liver disease and predicting their clinical course.
Abstract:
To assess the utility of the serum aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio in a group of infants with liver disorders, we retrospectively analyzed the charts of 73 infants with chronic liver disorders. Patients were considered as having either a good outcome (n = 40) or a poor outcome (n = 33), based upon the clinical course. AST and ALT in serum were measured simultaneously at the time of initial presentation and at various follow-up visits during the first 13 months after birth. At presentation (mean age 1.65 months), there was no difference in the AST/ALT ratios between the good (1.61 +/- 0.62; mean +/- SD) and poor (1.65 +/- 0.78) outcome groups (P = 0.81). However, over time, the AST/ALT ratio increased in patients in the poor-outcome group and decreased in patients in the good-outcome group. Calculating the AST/ALT ratio appears to be an easy, early, and reliable prognostic indicator for infants with hepatic disease, and may be a useful measure for evaluating liver-disease patients.